NEW YORK (GenomeWeb) – Rosetta Genomics announced today that its proposed merger with Genoptix has been scuttled after it failed to secure the necessary shareholder approval.

Rosetta said that as a result, it is obligated to reimburse Genoptix $750,000 in three installments, the first of which is due March 22. It added that Genoptix has indicated that it remains interested in pursuing a business arrangement with Rosetta, although it did not provide details about any potential deal.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Oct
02

In the last few years several molecular testing methodologies — such as immunohistochemistry, PCR, and sequencing — have been approved by the US Food and Drug Administration to aid in the management of patients with lung cancer.  

Oct
10

This webinar will provide a first-hand look at how the Dana-Farber Cancer Center is adapting its oncology care strategy in light of the rapidly evolving molecular landscape.

Nov
05
Sponsored by
Sophia Genetics

With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.